Carboplatin

Catalog No.S1215 Synonyms: JM-8, CBDCA, NSC 241240

Carboplatin Chemical Structure

Molecular Weight(MW): 371.25

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

Size Price Stock Quantity  
USD 77 In stock
USD 107 In stock
USD 167 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 29 Publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.
Features A DNA synthesis inhibitor.
Targets
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  NI\Oc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYeyMVI26oDLzszN MYC3NkBp MnfRbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NVnzS49jOjZzM{exNFU>
Tca8113/CBP  M2D0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXZTIp{Oi1{NfMAje69VQ>? MmjjO|IhcA>? NWfJdIYycW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NITReFQzPjF|N{GwOS=>
Tca8113/PYM  MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXGyMVI26oDLzszN NYnNV5hMPzJiaB?= M1;jUYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M4PMRVI3OTN5MUC1
SKOV3 Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3iemI3OCCvZz;tcC=> MUexMVUh\A>? NYDEVHlZcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgeIlu\SCmZYDlcoRmdnSueR?= NX;QXJdwOjZzM{ewOFM>
SKOV3 MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\zT|AuPCEQvHevcYw> MWiyOE81QC95MjDo NI\JRYFqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 NYThWZYyOjZzMkWyO|M>
SKOV3 NGPmUWVCeG:ydH;zbZMhSXO|YYm= MnniNkDPxGdxbXy= MkC4OFghcA>? NFH3e|NqdmS3Y3XzJIFxd3C2b4Ppdy=> Ml;HNlYyOjV{N{O=
OSA MoLXR4xwdm:pZX7pZ{BCe3OjeR?= Mn3FNk42NzVizszN MYTy[ZN2dHS|IHnuJIxwf2W{IHPvcI9vgSCob4LtZZRqd25iYYOgZ49ueGG{ZXSgeI8h\Wm2aHXyJGJOUTFic3nSUmEhfHKnYYTt[Y51 MXqyOlEyODZ{MB?=
A549 NVvJOVhMTnWldHnvckBCe3OjeR?= M1\0N|AwOjVxNUCg{txO Mme3NlQhcA>? MYPkc5dvemWpdXzheIV{KG2rUj2yNFUh\XiycnXzd4lwdsLi NXL1V2RNOjV7MUezNVc>
H1975 MljiSpVkfGmxbjDBd5NigQ>? MWiwM|I2NzVyIN88US=> MYSyOEBp MUPkc5dvemWpdXzheIV{KG2rUj2yNFUh\XiycnXzd4lwdsLi M3XDVVI2QTF5M{G3
A549 NVfQPZgyTnWldHnvckBCe3OjeR?= M1zMeFAwOjVxNUCg{txO NFjGVYczPCCq NWPQc4hTfXC{ZXf1cIF1\XNibXnSMVIyQCCneIDy[ZN{cW:w M3vQWVI2QTF5M{G3
H1975 Mo\5SpVkfGmxbjDBd5NigQ>? MX6wM|I2NzVyIN88US=> MYSyOEBp MW\1dJJm\3WuYYTld{BucVJvMkG4JIV5eHKnc4Ppc44> NXHWdFFQOjV7MUezNVc>
A549 M4fpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrzO5IzPSEQvF2= MVqyOEBp MWfpcohq[mm2czDj[YxtKGe{b4f0bC=> MWiyOVkyPzNzNx?=
H1975 M1LCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnhNlUh|ryP M37nRlI1KGh? MkPObY5pcWKrdIOgZ4VtdCCpcn;3eIg> NHfLd28zPTlzN{OxOy=>
MDA-MB-231 NGXaeZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnW0NE0zOjBizsznM41t MXy3NkBp NWjUemRiUUN3MNMgQUA5PiEQvF2= MmW1NlU5Ozd4OUG=
T47D MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jZWFAuOjJyIN88[{9udA>? MVG3NkBp MYDJR|UxyqB;IES4Mlkh|ryP MW[yOVg{PzZ7MR?=
LCTCC M2OxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\qO|NnUUN3ME2zMljjiIoEtV2= NWLxemZsOjV5N{OxOlc>
MCTCC M2D2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTBeZM3UUN3ME2yMljjiIoEtV2= MXOyOVc4OzF4Nx?=
MegTCC NFTFTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDSTWM2OD12LkJihKnDvU1? M3zaNVI2Pzd|MU[3
MonoTCC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;Kd|JKUUN3ME21MlbjiIoEtV2= NV3NZoxFOjV5N{OxOlc>
MCF7 NYqxc4VvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVOyNEDPxE1? Mn:1O|IhcA>? MmjtbY5lfWOnczDj[YxtKGSnYYToJI9nKEiSMd8yMYRmeGyndHXkJG1ETjdiY3XscJM> NUfxRZpLOjV5NkmwNlU>
A-549  MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrDTJhpOC53IN88US=> NIDmVVQzPCCq NFSzO|NFVVORwrC= M3nEO4lvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm= M3vNdVI2PzV3Nkmw
A-549  NHnuSFVCeG:ydH;zbZMhSXO|YYm= NXnORVhbOC53IN88US=> MkXXOFghcA>? NU\4WWJWTE2VT9Mg MmrQd4hwf3NiZXHycJkh[XCxcITvd4l{KG[nYYT1doV{KGmwY3z1[Ilv\yCkbHXiZolv\yCjbnSgZ4hzd22jdHnuJINwdmSnboPheIlwdg>? M1LwdlI2PzV3Nkmw
A-549  MUHGeYN1cW:wIFHzd4F6 M3nM[lAvPSEQvF2= Mn7IOFghcA>? MYXEUXNQyqB? MXTzbI94eyCjYnXydoFvfCCvaXPyc5R2[nWuZTDkbZNzfXC2aX;u MkTVNlU4PTV4OUC=
A-549  NYD3Vm1STnWldHnvckBCe3OjeR?= NIPTZosxNjVizszN NFnvdYU1QCCq MlPBSG1UV8Li MWfpcohq[mm2czDv[kBk\WyuIH3p[5JifGmxbtMg MoXjNlU4PTV4OUC=
RMG-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[0TWM2OD1{OD64JOKyKDNwNjDt[{9N NWSzNZNsOjV5Mk[5NVM>
FN-RMG-1 NG[zXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTRyLkWgxtEhPC5{IH3nM2wLKM7:TR?= M2rBTlI2PzJ4OUGz
RMG-1-hFUT Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;ET2lEPTB;NUiuNUDDuSB{LkSgcYcwVA>? NIDSfpYzPTd{NkmxNy=>
FN-RMG-1-hFUT NVLENotzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHRTWM2OD1zMUiuPEDDuSBzMz64JI1oN0x? MnnyNlU4OjZ7MUO=
CHP-134  MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnxVmkyKM7:TR?= M2LwPGROW00EoB?= Mn7mbY5pcWKrdIOgd4lodmmoaXPhcpQh[2WubDDndo94fGhiY3;tZolv\WRid3n0bEBIW0t{OEOwN|cy MXuyOVY2QDR4Mx?=
IMR-32 Ml3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWi3U3JpOSEQvF2= NYXl[4Z2TE2VT9Mg NYLyUYhscW6qaXLpeJMhe2mpbnnmbYNidnRiY3XscEBoem:5dHigZ49u[mmwZXSge4l1cCCJU1uyPFMxOzdz MYiyOVY2QDR4Mx?=
CHP-134  MVvGeYN1cW:wIFHzd4F6 MlyxNVAh|ryPwrC= MoLvSG1UV8Li MmS1bY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJGdUUzJ6M{CzO|E> M32zdVI2PjV6NE[z
IMR-32 M2jod2Z2[3Srb36gRZN{[Xl? M17lelExKM7:TdMg Mn7ISG1UV8Li MYrpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigS3NMOjh|MEO3NS=> M2P4d|I2PjV6NE[z
A549 M4HOcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{OwZlAvOi12MECwJO69VQ>? M2DldVczKGh? NILVbm9KSzVyPUGyOkDDuSB3LkCg{txO M2DoSlI2PjJ3MkSz
A549/CDDP M4fCUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVmwMlIuPDByMDFOwG0> MljIO|IhcA>? M{jYNGlEPTB;MkSwxsDDucLiNEWuO{DPxE1? M3[5RVI2PjJ3MkSz
H460  M3LWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfLc5YzPCCq M3rIdWROW09? NWfWdVVKUUN3ME23Mlkh|ryP NG\JNGUzPTV7OUm5OS=>
H460  NXraWJBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXneXBIPy57IN88US=> NYLVfIcyOjRiaB?= NXrJXHFSTE2VTx?= MYXzbI94eyCjIILh[Ilwe2Wwc3n0bZpqdmdiZX\m[YN1KHSxIGitdoF6ew>? M3;CSVI2PTl7OUm1
NRK-52E NVu4PJh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH1Vm14PzMEoHlCpC=> NXXKcWhYUUN3ME2xNFAhyrFiMUKuPUDPxE1? MW[yOVU3PTZyMx?=
RGE MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f0RVczyqCqwrC= MlrTTWM2OD1{MjFCtUA4NjRizszN MmLFNlU2PjV4MEO=
NRK-52E M1jhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUG3NuKhcMLi MoDGTWM5OD1zN{mgxtEhQS53IN88US=> NXLvNHFbOjV3NkW2NFM>
RGE NF3jcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\hNFM4OsLiaNMg NXXRbIdkUUN6ME22N{DDuSB5LkSg{txO Mn7sNlU2PjV4MEO=
SK-OV-3 NUH3UIZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojHO|IhcA>? NWm2Xm5YUUN3ME2xNFQvQCEQvF2= NWjVfJlCOjV3MkCxN|I>
ES-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfoO|IhcA>? NH;6S|JKSzVyPUG0MlYh|ryP M2nkXlI2PTJyMUOy
OVCAR-8 NGnUeIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7hPYE4OiCq NImw[GpKSzVyPUm2MlAh|ryP MVyyOVUzODF|Mh?=
3AO NUfIblNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLwO|IhcA>? MonuTWM2OD14Mz60JO69VQ>? Ml;sNlU2OjBzM{K=
A2780 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIroTGM4OiCq M1jDbGlEPTB;MUS1Mlch|ryP NHe2RYIzPTV{MEGzNi=>
SW626 NGDBbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVj4R|E6PzJiaB?= MkjaTWM2OD17Nz6wJO69VQ>? M4TG[lI2PTJyMUOy
OVCAR-3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLuO|IhcA>? MWjJR|UxRTN{Lk[g{txO Mn7vNlU2OjBzM{K=
A549 NF3TTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[2d2lEPTB;MUWxMlU3KMLzIEWzMlA3KM7:TR?= MVmyOVI4PzR4MR?=
4T1 NYPRdlJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr3TFB[UUN3ME24OE43OiEEsTCzNE4xPSEQvF2KJO69VQ>? MX6yOVI4PzR4MR?=
BALB/3T3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvJTYxKSzVyPUG0MlMxKMLzIE[uOlgh|ryP MoXDNlUzPzd2NkG=
B16 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXaSGx5UUN3ME22OE4{OCEEsTC2MlgyKM7:TR?= NYXafmNZOjV{N{e0OlE>
DU 145 NHvOOXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT2TWM2OD1|NT6wOEDDuSBzNz61OEDPxE1? MXGyOVI4PzR4MR?=
FaDu M{LPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfoN|hKSzVyPUS1MlM6KMLzIEGxMlUxKM7:TR?= MVmyOVI4PzR4MR?=
HCV-29T MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmntTWM2OD12OD61O{DDuSB{Mj60PUDPxE1? MnnMNlUzPzd2NkG=
HL-60 NUDlelNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2G5PWlEPTB;MUGuNVAhyrFiND60O{DPxE1? Mmq4NlUzPzd2NkG=
HT-29 M3L4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTh7LkG2JOKyKDF6Lki2JO69VQ>? NF7pOFUzPTJ5N{S2NS=>
H146 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jyc2lEPTB;NEmuOuKyOTNwMTFOwG0> M2fLPFI2OTJ2Mkiy
H187 NHi1OndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jJdGlEPTB;MUKuO:KyOi55IN88US=> NVHzc|RDOjVzMkSyPFI>
H128 NH\sOllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmH3TWM2OD1zME[uOOKyQS54IN88US=> NHX6[nUzPTF{NEK4Ni=>
H69 M2[4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTd4LkpCtVI4NjhizszN M1TN[lI2OTJ2Mkiy
H209 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDQN2JKSzVyPUK1PE4yyrF7OT64JO69VQ>? NYLRPFF4OjVzMkSyPFI>
DMS153 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTV5LklCtVkvOiEQvF2= NHrlTG8zPTF{NEK4Ni=>
H526 NYS5UJM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HYPWlEPTB;Nz6yxtEyNjdizszN NE\mZYMzPTF{NEK4Ni=>
DMS114 NFHwT3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPJTWM2OD16NT64xtEyOi56IN88US=> M17ycFI2OTJ2Mkiy
DMS53 NHKxN4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXYSmRKSzVyPUG0Ok4zyrF|Nj60JO69VQ>? NI\MeZczPTF{NEK4Ni=>
HeLa NIe3ZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHjeGtYPS16MDFOwG0> M1LJd4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MnH6NlUyODl|NkC=
MCF-7 M1vCT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWntS4lOPS16MDFOwG0> MWPpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NVvRdoQxOjVzMEmzOlA>
MDA-MB-231 M2fueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XtTlUuQDBizszN M{KydYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M3jLV|I2OTB7M{[w
CaOV3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr5VlM4OiCq M2DNc2lEPTB;OE[uNUDPxE1? MnTYNlUxPjh6NEm=
OVCAR-3 NXvlZ49NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq2eoJrPzJiaB?= NEe1S2ZKSzVyPUG3PU42KM7:TR?= M1z2fVI2ODZ6OES5
OVCAR-5 MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYG3NkBp Ml3CTWM2OD15NT63JO69VQ>? MlnCNlUxPjh6NEm=
SKOV-3 M1PV[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvDV5Z4PzJiaB?= MYPJR|UxRTVyNDFOwG0> MYqyOVA3QDh2OR?=
OVCAR-4 MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHiVFM4OiCq NGXYT|ZKSzVyPUK5NE43KM7:TR?= MXOyOVA3QDh2OR?=
OVCAR-8 NXvXSZpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVS0[pJiPzJiaB?= M1fKdWlEPTB;NkmwMlIh|ryP MoL6NlUxPjh6NEm=
MA148 NF3UNpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYKyOEBp MXjJR|UxRTh|LkdihKnDueLCiUGuOEDPxGdxbXy= M3fOV|I1QDNzMEmx
A549 NYPDb|htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV6yOEBp M17lXmlEPTB;N{e2MlDjiIoEsfMAjVEvQSEQvHevcYw> MkDHNlQ5OzFyOUG=
MDA-MB-231 NE[3SIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXe0WI93OjRiaB?= MkfmTWM2OD15NEiuNQKBkcLz4pEJNU4yKM7:Zz;tcC=> NFX0W2YzPDh|MUC5NS=>
NCI-ADR/RES  NFu5V|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPFS2tyOjRiaB?= NVGzNo5KUUN3ME2xO|U{NjEkgJpCtgKBkTRwNDFOwIcwdWx? NXy4OWJGOjR6M{GwPVE>
MA148 NIX1SpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVy0PEBp NX60NIh1UUN3ME2yPE4y6oDLwsJihKkyNjBizsznM41t NGfnRoIzPDh|MUC5NS=>
A549 NV[yO45MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{OyR|Q5KGh? NV[2XIdUUUN3ME2xNVgvOOLCidMx5qCKOS5{IN88[{9udA>? NWnpW4t4OjR6M{GwPVE>
MDA-MB-231 NGT5XYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7OVIo1QCCq MnjrTWM2OD1zOEOuNQKBkcLz4pEJNU4zKCEQvHevcYw> MXqyOFg{OTB7MR?=
NCI-ADR/RES  M1LOfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1u4bVQ5KGh? MkK2TWM2OD1zOUOuNQKBkcLz4pEJNU46KM7:Zz;tcC=> M3PZPFI1QDNzMEmx
MA148 NGnUd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHrO|IhcA>? MlXkTWM2OD1zMz635qCKyrIkgJmxMlIh|rypL33s M{fBNVI1QDNzMEmx
A549 M1jP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvXeWFbPzJiaB?= MWDJR|UxRTZ2LkRihKnDueLCiUGuNUDPxGdxbXy= NEfSdW4zPDh|MUC5NS=>
MDA-MB-231 MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF21TGk4OiCq MX3JR|UxRTl7LkZihKnDueLCiUGuNUDPxGdxbXy= M4G2XFI1QDNzMEmx
NCI-ADR/RES  Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jpSVczKGh? M2DwWGlEPTB;M{euOQKBkcLz4pEJNU44KM7:Zz;tcC=> M2HrRlI1QDNzMEmx
A549 MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjzT|Y4OiCq MWDEUXNQ MYLJR|UxRTF3Mj60NFkh|ryP M4PyelI1PzJzM{Kz
NCI-H157 NGrLdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYe3NkBp NVvrNnM2TE2VTx?= M1viNmlEPTB;OEmuPVc4KM7:TR?= NXLpXJpyOjR5MkGzNlM>
PC9 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInNU|A4OiCq Mki5S2M2OD15MT62xtE6NjViwsXN M2PrTFI1PjF6OEC5
A549  NVj4bYQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[zc4NOPzJiaB?= MUTHR|UxRTF|NtMxN|EvPiEEtV5CpC=> MX6yOFYyQDhyOR?=
PC9 M4Sw[2Fxd3C2b4Ppd{BCe3OjeR?= M1i4UVExOCEEtV2= MknGO|IhcA>? M17kOIlv\HWlZYOgZZBweHSxc3nz M{HlSlI1PjF6OEC5
A549  M1KyPWFxd3C2b4Ppd{BCe3OjeR?= NGPKclAyODBiwsXN MX63NkBp NVHvO4VIcW6mdXPld{BieG:ydH;zbZM> Mkn3NlQ3OTh6MEm=
A549 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWWyOEBp NGrQRXJKSzFyPUGuOFc3KG6P M{DaTVI1Ozl4NEO3
H1299 M2HafWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVWyOEBp M1e0NWlEOTB;MD60OFMhdk1? NYnhTmFyOjR|OU[0N|c>
HCC15 NWnPbpNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3RVWYzPCCq NX7S[VJSUUNzME2wMlM1PiCwTR?= MmXENlQ{QTZ2M{e=
H157 M3jLRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTafZJWOjRiaB?= M1rFUWlEOTB;MD64NUBvVQ>? MlHvNlQ{QTZ2M{e=
A2780 M3\1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPvTWM2OD1zND6w5qCKyrIkgJmxMlQh|ryP NFnvRoozPDJyOU[5Ny=>
A2780cisR NYPWVXUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1S5NGlEPTB;NEiuPgKBkcLz4pEJN{46KM7:TR?= M4LRUFI1OjB7Nkmz
A2780ZD0473R M2jSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTaVoJKSzVyPU[0MlbjiIoEsfMAjVMvOiEQvF2= MXeyOFIxQTZ7Mx?=
SKOV-3 MmLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWftUo5CUUN3ME20N{416oDLwsJihKk{NjlizszN NF;FTFMzPDJyOU[5Ny=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pChK-2 / Chk-2 ; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated Chk-2. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ

p-p53(S15) / p-p53(S46) / p-p53(S392) / p53; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated p-p53. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ

p-p38 / p38 / Cleaved PARP / PARP ; 

PubMed: 30049957     


A2780s and A2780cp cells were treated with increasing concentrations of carboplatin for 48 h. Phosphorylation of p38 and cleavage of Poly(ADP-ribose) polymerase (PARP) were analyzed by Western blotting. Two antibodies were used to examine the cleaved PARP䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋Ð㺣痖�෋€𢡄�෋€䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemセ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒セ᎒�堞ﻮ᎒፲露𢡄

30049957
Immunofluorescence
γH2AX ; 

PubMed: 24348048     


Carboplatin induced DNA damage in SiHa cells. SiHa cells were exposed to 20, 40, and 80 μmol/L carboplatin for 12 hours, respectively. Immunofluorescence analysis was used to detect nuclear γ-H2AX foci formation with anti-H2AX antibody (red, fluorescein i䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ

24348048
Growth inhibition assay
Cell viability ; 

PubMed: 24348048     


SiHa and CaSki cells were treated with the indicated concentrations of carboplatin for 72 hours, and cell viability was measured by Cell Counting Kit-8 viability assay. 

24348048
In vivo In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: A2780, SKOV3, IGROV-1 and HX62
  • Concentrations: 0-200 μM
  • Incubation Time: 72 hours
  • Method:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • Formulation: Carboplatin is dissolved in 43% ethanol, 33% polypropylene glycol and 24% cremaphor diluted 1:7 with sterile water.
  • Dosages: ≤60 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 14 mg/mL warmed (37.71 mM)
DMSO Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.25
Formula

C6H12N2O4Pt

CAS No. 41575-94-4
Storage powder
temperature in solvent (should be freshly prepared each time)
Synonyms JM-8, CBDCA, NSC 241240

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03968653 Recruiting Drug: Debio 0123|Drug: Carboplatin Advanced Solid Tumors Debiopharm International SA July 30 2019 Phase 1
NCT03723967 Recruiting Drug: Durvalumab with Carboplatin/Paclitaxel Squamous Cell Carcinoma of the Head and Neck Centre Leon Berard May 16 2019 Phase 2
NCT03694834 Suspended Drug: Pembrolizumab|Procedure: Hysterectomy Endometrial Cancer|Uterine Cancer UNC Lineberger Comprehensive Cancer Center|Merck Sharp & Dohme Corp. March 29 2019 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you advise what solvent to use and the concentration for S1215 for in vitro use?

  • Answer:

    DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Carboplatin | Carboplatin supplier | purchase Carboplatin | Carboplatin cost | Carboplatin manufacturer | order Carboplatin | Carboplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID